Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2010, Article ID 426804, 4 pages
http://dx.doi.org/10.1155/2010/426804
Case Report

Adverse Interaction between Capecitabine and Warfarin Resulting in Altered Coagulation Parameters: A Review of the Literature Starting from a Case Report

ASL 10, “Veneto Orientale”, Hospice Oncologico, Portogruaro, Borgo San Gottardo 44, Venice, Italy

Received 12 March 2010; Accepted 16 June 2010

Academic Editor: Estella M. Matutes

Copyright © 2010 Giovanni Giunta. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M.tempspacetempspaceS. Copur, P. Ledakis, and P. Ledakis, “An adverse interaction between warfarin and capecitabine: a case report and review of the literature,” Clinical Colorectal Cancer, vol. 1, no. 3, pp. 182–184, 2001. View at Google Scholar · View at Scopus
  2. H.tempspacetempspaceC.tempspacetempspaceE. Buyck, N. Buckley, M.tempspacetempspaceD. Leslie, and P.tempspacetempspaceN. Plowman, “Capecitabine-induced potentiation of warfarin,” Clinical Oncology, vol. 15, no. 5, p. 297, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Isaacs and N. Haim, “Adverse interaction between capecitabine and warfarin resulting in altered coagulation parameters and bleeding: case report and review of the literature,” Journal of Chemotherapy, vol. 17, no. 3, pp. 339–342, 2005. View at Google Scholar · View at Scopus
  4. L.tempspacetempspaceM. Janney and N.tempspacetempspaceV. Waterbury, “Capecitabine-warfarin interaction,” Annals of Pharmacotherapy, vol. 39, no. 9, pp. 1546–1551, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. Y. Yildirim, O. Ozyilkan, Z. Akcali, and B. Basturk, “Drug interaction between capecitabine and warfarin: a case report and review of the literature,” International Journal of Clinical Pharmacology and Therapeutics, vol. 44, no. 2, pp. 80–82, 2006. View at Google Scholar · View at Scopus
  6. H.tempspacetempspaceR. Shah, L. Ledbetter, R. Diasio, and M.tempspacetempspaceW. Saif, “A retrospective study of coagulation abnormalities in patients receiving concomitant capecitabine and warfarin,” Clinical Colorectal Cancer, vol. 5, no. 5, pp. 354–358, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Levine, J. Hirsh, and J. Hirsh, “Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer,” Lancet, vol. 343, no. 8902, pp. 886–889, 1994. View at Publisher · View at Google Scholar · View at Scopus
  8. M.tempspacetempspaceM. Bern, J.tempspacetempspaceJ. Lokich, and J.tempspacetempspaceJ. Lokich, “Very low doses of warfarin can prevent thrombosis in central venous catheters.tempspacetempspaceA randomized prospective trial,” Annals of Internal Medicine, vol. 112, no. 6, pp. 423–428, 1990. View at Google Scholar · View at Scopus
  9. G. Pentheroudakis and C. Twelves, “The rational development of capecitabine from the laboratory to the clinic,” Anticancer Research, vol. 22, no. 6 B, pp. 3589–3596, 2002. View at Google Scholar · View at Scopus
  10. R. Petrioli, G. Bargagli, and S. Lazzi, “Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin.tempspacetempspaceMultidisciplinary Oncology Group in Gastrointestinal Tumors,” Anticancer Drugs, vol. 21, pp. 313–319, 2010. View at Google Scholar
  11. R. Camidge, B. Reigner, J. Cassidy, S. Grange, M. Abt, E. Weidekamm, and D. Jodrell, “Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer,” Journal of Clinical Oncology, vol. 23, no. 21, pp. 4719–4725, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. A.tempspacetempspaceK. Wittkowsky, “Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions,” Seminars in Vascular Medicine, vol. 3, no. 3, pp. 221–230, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. R.tempspacetempspaceA. O'reilly, P.tempspacetempspaceM. Aggeler, and L.tempspacetempspaceS. Leong, “Studies on the coumarin anticoagulant drugs: the pharmacodynamics of warfarin in man,” The Journal of Clinical Investigation, vol. 42, pp. 1542–1551, 1963. View at Google Scholar · View at Scopus
  14. N.tempspacetempspaceH.tempspacetempspaceG. Holford, “Clinical pharmacokinetics and pharmacodynamics of warfarin.tempspacetempspaceUnderstanding the dose-effect relationship,” Clinical Pharmacokinetics, vol. 11, no. 6, pp. 483–504, 1986. View at Google Scholar · View at Scopus
  15. J.tempspacetempspaceA. Baron, G. Gridley, E. Weiderpass, O. Nyrén, and M. Linet, “Venous thromboembolism and cancer,” Lancet, vol. 351, no. 9109, pp. 1077–1080, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. B.tempspacetempspaceA. Hutten, M.tempspacetempspaceH. Prins, M. Gent, J. Ginsberg, J.tempspacetempspaceG.tempspacetempspaceP. Tijssen, and H.tempspacetempspaceR. Buller, “Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved International Normalized Ratio: a retrospective analysis,” Journal of Clinical Oncology, vol. 18, no. 17, pp. 3078–3083, 2000. View at Google Scholar · View at Scopus
  17. S.tempspacetempspaceA. Mousa, “Anticoagulants in thrombosis and cancer: the missing link,” Seminars in Thrombosis and Hemostasis, vol. 28, no. 1, pp. 45–52, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. G. Masci, M. Magagnoli, and M. Magagnoli, “Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy?” Journal of Clinical Oncology, vol. 21, no. 4, pp. 736–739, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Magagnoli, G. Masci, C. Carnaghi, P.tempspacetempspaceA. Zucali, L. Castagna, E. Morenghi, and A. Santoro, “Minidose warfarin is associated with a high incidence of International Normalized Ratio elevation during chemotherapy with FOLFOX regimen,” Annals of Oncology, vol. 14, no. 6, pp. 959–960, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. J.tempspacetempspaceM. Kolesar, C.tempspacetempspaceL. Johnson, B.tempspacetempspaceL. Freeberg, J.tempspacetempspaceD. Berlin, and J.tempspacetempspaceH. Schiller, “Warfarin-5-FU interaction—a consecutive case series,” Pharmacotherapy, vol. 19, no. 12, pp. 1445–1449, 1999. View at Google Scholar · View at Scopus
  21. M. Magagnoli, G. Masci, L. Castagna, S. Bramanti, E. Morenghi, C. Carnaghi, and A. Santoro, “High incidence of haemostatic interference in cancer patients treated with FOLFOX regimen and concomitant minidose of warfarin,” British Journal of Haematology, vol. 129, no. 5, pp. 709–710, 2005. View at Publisher · View at Google Scholar · View at PubMed
  22. M. Magagnoli, G. Masci, L. Castagna, P.tempspacetempspaceA. Zucali, E. Morenghi, V. Pedicini, and A. Santoro, “Prophylaxis of central venous catheter-related thrombosis with minidose warfarin: analysis of its use in 427 cancer patients,” Anticancer Research, vol. 25, no. 4, pp. 3143–3148, 2005. View at Google Scholar
  23. A. Afsar, C. Lee, and D.tempspacetempspaceS. Riddick, “Modulation of the expression of constitutive rat hepatic cytochrome P450 isozymes by 5-fluorouracil,” Canadian Journal of Physiology and Pharmacology, vol. 74, no. 2, pp. 150–156, 1996. View at Publisher · View at Google Scholar
  24. Q. Zhou and E. Chan, “Effect of 5-fluorouracil on the anticoagulant activity and the pharmacokinetics of warfarin enantiomers in rats,” European Journal of Pharmaceutical Sciences, vol. 17, no. 1-2, pp. 73–80, 2002. View at Publisher · View at Google Scholar
  25. H.tempspacetempspaceR. Shah, L. Ledbetter, R. Diasio, and M.tempspacetempspaceW. Saif, “A retrospective study of coagulation abnormalities in patients receiving concomitant capecitabine and warfarin,” Clinical Colorectal Cancer, vol. 5, no. 5, pp. 354–358, 2006. View at Publisher · View at Google Scholar
  26. M. Nakajima, T. Genda, and M. Suehira, “Increased anticoagulant activity of warfarin used in combination with doxifluridine,” Cancer Chemotherapy and Pharmacology.tempspacetempspaceIn press.